Inhibitors of lrrk2 kinase

A compound having the following Structure (I):

• or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof, wherein:
• A is phenylene or 5 or 6-membered heteroarylene;
• B is C3-C8 monocyclic cycloalkyl optionally substituted with one or more substituents selected from amino, halo, hydroxyl, oxo, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxylalkyl, C1-C6 aminoalkyl, C1-C6 alkylaminylalkyl, C1-C6 alkoxy;
• C1-C6 haloalkoxy, C1-C6 alkylcarbonyl, C1-C6 haloalkylcarbonyl, C1-C6 alkylaminyl, C1-C6 haloalkylaminyl, C1-C6 alkylcarbonylaminyl, C1-C6 haloalkylcarbonylaminyl, C3-C8 cycloalkyl, C3-C8 cycloalkylcarbonyl, C3-C8 halocycloalkylaminyl, and C3-C8 cycloalkylcarbonylaminyl;
• L is a direct bond;
• R1a and R1b are each independently H, halo, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C8 cycloalkyl;
• and
• R2 is 3-8-membered heterocyclyl optionally substituted with one or more substituents selected from halo, cyano, C1-C6 alkyl, hydroxyl, alkoxy, and C1-C6 haloalkyl.